[go: up one dir, main page]

PE20131034A1 - THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER - Google Patents

THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER

Info

Publication number
PE20131034A1
PE20131034A1 PE2013000084A PE2013000084A PE20131034A1 PE 20131034 A1 PE20131034 A1 PE 20131034A1 PE 2013000084 A PE2013000084 A PE 2013000084A PE 2013000084 A PE2013000084 A PE 2013000084A PE 20131034 A1 PE20131034 A1 PE 20131034A1
Authority
PE
Peru
Prior art keywords
interferon
represented
polyethylene glycol
interferon alpha
positional isomer
Prior art date
Application number
PE2013000084A
Other languages
Spanish (es)
Inventor
Tatyana Veniaminovna Chernovskaya
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Angelina Vsevolodovna Klenova
Dmitriy Valentinovich Morozov
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131034(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of PE20131034A1 publication Critical patent/PE20131034A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UN CONJUGADO ESTABLE DE INTERFERON-ALFA PEGILADO DE FORMULA (1), DONDE n TIENE VALORES INTEGRALES DE 227 A 10000; m TIENE UN VALOR MAYOR O IGUAL A 4; NALFAH-IFN ES EL INTERFERON ALFA. EL INTERFERON ALFA ES UN INTERFERON a-2b NATURAL O RECOMBINANTE. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO CONJUGADO, ACETATO DE SODIO TRIHIDRATO, ACIDO ACETICO, ENTRE OTROS. DICHO CONJUGADO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES ONCOLOGICAS, VIRALES E INMUNOLOGICASREFERRING TO A STABLE CONJUGATE OF INTERFERON-PEGILATED ALPHA OF FORMULA (1), WHERE n HAS INTEGRAL VALUES FROM 227 TO 10000; m HAS A VALUE GREATER OR EQUAL TO 4; NALFAH-IFN IS THE INTERFERON ALPHA. THE ALPHA INTERFERON IS A NATURAL OR RECOMBINANT a-2b INTERFERON. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES SAID CONJUGATE, SODIUM TRIHYDRATE ACETATE, ACETIC ACID, AMONG OTHERS. SAID CONJUGATE IS USEFUL IN THE TREATMENT OF ONCOLOGICAL, VIRAL AND IMMUNOLOGICAL DISEASES

PE2013000084A 2010-07-20 2010-09-24 THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER PE20131034A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129824/10A RU2447083C1 (en) 2010-07-20 2010-07-20 NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON

Publications (1)

Publication Number Publication Date
PE20131034A1 true PE20131034A1 (en) 2013-09-27

Family

ID=45497062

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000084A PE20131034A1 (en) 2010-07-20 2010-09-24 THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER

Country Status (20)

Country Link
KR (1) KR101586372B1 (en)
CN (1) CN102617736B (en)
AR (1) AR087227A1 (en)
BR (1) BRPI1101565A2 (en)
CO (1) CO6680611A2 (en)
CR (1) CR20130021A (en)
CU (1) CU24193B1 (en)
DO (1) DOP2013000002A (en)
EA (1) EA020257B1 (en)
EC (1) ECSP13012398A (en)
MX (1) MX2011007458A (en)
MY (1) MY168784A (en)
NI (1) NI201300008A (en)
PE (1) PE20131034A1 (en)
PH (1) PH12012502425A1 (en)
RU (1) RU2447083C1 (en)
SG (1) SG187117A1 (en)
UA (1) UA99766C2 (en)
UY (1) UY33525A (en)
WO (1) WO2012011836A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515913C1 (en) * 2013-03-22 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS)
EA021643B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Monopegylated interferon-alpha of linear structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity
EA021610B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Liquid antiviral formulation
CN103463623B (en) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 A kind of Peg-IFN alpha-2b injection and preparation method thereof
RU2554761C1 (en) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Anti-enteroviral and immunostimulating agent
RU2572800C1 (en) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" New formulation containing polyethylene glycol (peg) conjugated interferon alpha-2beta characterised by less painful administration
EA029498B1 (en) * 2015-11-24 2018-04-30 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) ANTI-TUMOUR DRUG BASED ON RECOMBINANT INTERFERON ALPHA-2b IN THE FORM OF MICROPARTICLES FOR PARENTERAL ADMINISTRATION
RU2678332C1 (en) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof
CA3184298A1 (en) * 2020-04-20 2021-10-28 Altum Pharmaceuticals Inc. Recombinant interferon
CN114392237B (en) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 Freeze-dried virus preparation and preparation method thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
JP2758154B2 (en) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
KR100974843B1 (en) * 2002-09-09 2010-08-11 넥타르 테라퓨틱스 Water Soluble Polymer Alkanal
RU2311930C2 (en) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Pagylated interferon against viral infection
JP2008509889A (en) * 2004-06-30 2008-04-03 イージェン コーポレーション PEGylated interferon alpha-1b
DE602006013151D1 (en) * 2005-07-19 2010-05-06 Nektar Therapeutics METHOD FOR PRODUCING POLYMERMALIMIDES
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease
CN101491682A (en) * 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 PEG-IFN omega conjugate and preparation technique thereof
CN101591387A (en) * 2008-05-28 2009-12-02 中国人民解放军军事医学科学院微生物流行病研究所 Pegylated recombinant human interferon omega conjugate
CN101514229B (en) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 Human interferon alpha derivative and polyethylene glycol modified substance thereof

Also Published As

Publication number Publication date
EA201100809A1 (en) 2012-01-30
CN102617736B (en) 2015-11-25
DOP2013000002A (en) 2013-09-15
EA020257B1 (en) 2014-09-30
CU20130013A7 (en) 2013-04-19
CO6680611A2 (en) 2013-05-31
ECSP13012398A (en) 2013-05-31
MX2011007458A (en) 2012-01-19
HK1170504A1 (en) 2013-03-01
CN102617736A (en) 2012-08-01
KR20130056885A (en) 2013-05-30
UA99766C2 (en) 2012-09-25
NI201300008A (en) 2014-05-26
KR101586372B1 (en) 2016-01-18
CU24193B1 (en) 2016-09-30
UY33525A (en) 2012-02-29
CR20130021A (en) 2013-02-20
PH12012502425A1 (en) 2013-07-08
SG187117A1 (en) 2013-02-28
RU2447083C1 (en) 2012-04-10
WO2012011836A1 (en) 2012-01-26
RU2010129824A (en) 2012-01-27
BRPI1101565A2 (en) 2012-12-04
MY168784A (en) 2018-12-04
AR087227A1 (en) 2014-03-12

Similar Documents

Publication Publication Date Title
PE20131034A1 (en) THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER
DOP2012000011A (en) PHARMACEUTICAL FORMULATION
JOP20200039A1 (en) Pharmaceutical preparation containing recombinant HCG
CL2012002489A1 (en) Compounds derived from silyl naphtho-imidazole; pharmaceutical composition; and its use to prevent or treat a hepatitis c virus infection.
AR081200A1 (en) INSULIN FORMULATIONS OF PROLONGED ACTION
BR112013031268A8 (en) polypeptides
CY1113449T1 (en) ANTI-VISUAL COMPOSITIONS CONTAINING GERANIOL AND CARBON
CO6501124A2 (en) IMMUNOMODULATING POLYPEPTIDES DERIVED IS THE IL 2 AND ITS THERAPEUTIC USE IN CANCER AND IN CHRONIC INFECTIONS
BR112012016853A2 (en) "pharmaceutical compositions for oral administration of insulin peptides".
BR112014013780A2 (en) syringe carrier
BR112015016930A2 (en) stabilized pharmaceutical formulations of insulin analogues and / or insulin derivatives
PE20120204A1 (en) METHOD AND FORMULATION TO REDUCE THE AGGREGATION OF A MACROMOLECLE UNDER PHYSIOLOGICAL CONDITIONS
MX366906B (en) Purification of iduronate-2-sulfatase.
CO2020008308A2 (en) Modified lipidated relaxin b-chain peptides and their therapeutic use
BR112015018259A2 (en) REDUCED PRO-INFLAMMATORY RESPONSE
CL2011002213A1 (en) Crystalline addition salt of (i) tromethamine with (ii) a derivative of azabiphenylaminobenzoic acid; pharmaceutical composition comprising salt and other therapeutic agents; pharmaceutical combination; and its use for the treatment of rheumatoid arthritis, psoriasic arthritis, ankylosing spondylitis, multiple sclerosis, among others
PE20130379A1 (en) METHODS FOR THE TREATMENT OF DIABETIC FOOT ULCERS
AR114324A1 (en) MODIFIED LIPIDED RELAXIN B-CHAIN PEPTIDES AND THEIR THERAPEUTIC USE
BR112012013199A8 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
RU2014129620A (en) COMPOSITIONS CONTAINING AMORPHIC EMODEPSIDE
UA118542C2 (en) Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein
UA109760C2 (en) BIOLOGICALLY ACTIVE peptide complexes
EA201590790A1 (en) STABLE PHARMACEUTICAL COMPOSITION BASED ON PEG-INTERFERON ALPHA-2b
HRP20241042T1 (en) Novel insulin analogues and uses thereof
BR112015014092A2 (en) transmucosal oral administration of glatiramer acetate

Legal Events

Date Code Title Description
FC Refusal